# Product Requirements Document: AI Assistant for I-131 Radionuclide Therapy

## 1. Executive Summary

### 1.1 Product Vision
Develop an AI-powered clinical decision support system specialized for I-131 (radioiodine) therapy in nuclear medicine, focusing on patient triage, preparation guidance, safety workflows, and clinician support. The system will serve as a comprehensive assistant for both healthcare providers and patients throughout the I-131 therapy journey.

### 1.2 Target Users
- **Primary**: Nuclear medicine physicians, endocrinologists, medical technologists
- **Secondary**: Nursing staff, radiation safety officers, patients and caregivers
- **Tertiary**: Hospital administrators, pharmacy staff

### 1.3 Key Objectives
- Improve patient safety through systematic screening and preparation protocols
- Standardize clinical workflows according to international guidelines
- Enhance patient education and compliance with safety instructions
- Reduce medical errors through automated eligibility checking
- Streamline radiation safety documentation and monitoring

## 2. Product Scope and Guardrails

### 2.1 Primary Use Cases (MVP)
1. **Patient Eligibility Screening**: Automated contraindication checking and risk assessment
2. **Preparation Protocol Management**: Low-iodine diet guidance, TSH stimulation protocols
3. **Safety Workflow Support**: Radiation safety instructions, isolation protocols
4. **Patient Education**: Interactive preparation and post-therapy guidance
5. **Clinical Documentation**: Structured note generation, consent highlights

### 2.2 Safety Guardrails
- **Non-diagnostic Device**: No autonomous clinical decisions or dose prescriptions
- **Decision Support Only**: All outputs require explicit clinician confirmation
- **Transparent References**: All recommendations include source guidelines and versioning
- **High-risk Alerts**: Explicit warnings for pregnancy, breastfeeding, severe contraindications
- **Audit Trail**: Complete logging of all system interactions and override decisions

### 2.3 Regulatory Positioning
- Clinical Decision Support (CDS) tool under FDA Software as Medical Device framework
- Compliance with AERB (India) radiation safety guidelines
- HIPAA/GDPR privacy compliance with encrypted PHI handling
- Medical advisory board oversight with versioned knowledge base

## 3. Clinical Pathways and Knowledge Architecture

### 3.1 I-131 Therapy Indications
#### 3.1.1 Differentiated Thyroid Cancer (DTC)
- **Remnant Ablation**: Post-surgical thyroid tissue destruction (30-100 mCi)
- **Adjuvant Therapy**: High-risk patients with microscopic disease (75-150 mCi)
- **Metastatic Disease**: Known distant metastases (100-200 mCi)

#### 3.1.2 Hyperthyroidism
- **Graves' Disease**: First-line or post-antithyroid failure (5-30 mCi)
- **Toxic Multinodular Goiter**: Definitive therapy (10-30 mCi)
- **Toxic Adenoma**: Single toxic nodule treatment (10-25 mCi)

### 3.2 Eligibility Criteria and Contraindications
#### 3.2.1 Absolute Contraindications
- **Pregnancy**: Confirmed or suspected (mandatory β-hCG testing)
- **Breastfeeding**: Active lactation (discontinue 6 weeks prior)
- **Vomiting/Diarrhea**: Risk of incomplete absorption or contamination
- **No Iodine Uptake**: Anaplastic or medullary thyroid carcinomas

#### 3.2.2 Relative Contraindications
- **Severe Renal Impairment**: eGFR < 30 mL/min/1.73m²
- **Recent Iodine Exposure**: CT contrast within 4-8 weeks
- **Drug Interactions**: Amiodarone, lithium, anti-thyroid medications
- **Severe Cardiac Disease**: Risk of thyroid storm

### 3.3 Patient Preparation Protocols
#### 3.3.1 TSH Stimulation (Target TSH >30 mIU/L)
- **Thyroid Hormone Withdrawal (THW)**:
  - Stop levothyroxine 4-6 weeks prior
  - Optional liothyronine bridge (2 weeks)
  - Monitor for hypothyroid symptoms
  
- **Recombinant Human TSH (rhTSH)**:
  - Two 0.9mg injections (days -2 and -1)
  - Continue thyroid hormone replacement
  - Preferred for elderly/cardiac patients

#### 3.3.2 Low-Iodine Diet (LID)
- **Duration**: 4-14 days pre-therapy (institutional variation)
- **Target**: <50 μg iodine daily intake
- **Restrictions**: Seafood, iodized salt, dairy, egg yolks, soy
- **Monitoring**: 24-hour urinary iodine excretion <50 μg (optional)

#### 3.3.3 Drug Discontinuation
- **Anti-thyroid medications**: Stop 5-7 days prior
- **Iodine-containing medications**: 2-8 weeks depending on agent
- **Supplements**: Multivitamins, kelp, iodine-containing products

### 3.4 Post-Therapy Monitoring and Safety
#### 3.4.1 Discharge Criteria (AERB India Guidelines)
- **Radiation Survey**: <50 μSv/h (5 mR/h) at 1 meter
- **Observation Period**: Minimum 2 hours post-administration
- **Documentation**: Written safety instructions provided

#### 3.4.2 Patient Safety Instructions (7-day period)
- **Isolation**: Sleep alone, maintain 2-meter distance from others
- **Hygiene**: Double toilet flushing, separate laundry
- **Contact Restrictions**: Avoid pregnant women, children <12 years
- **Travel**: Airport screening documentation, public transport limitations

#### 3.4.3 Follow-up Schedule
- **Short-term**: Thyroid function tests 4-6 weeks
- **Intermediate**: Thyroglobulin, imaging 3-6 months
- **Long-term**: Annual monitoring for recurrence/metastases

## 4. Technical Requirements

### 4.1 Data Inputs
#### 4.1.1 Patient Demographics
- Age, gender, weight, pregnancy status
- Medical history, comorbidities, allergies
- Prior thyroid surgeries and I-131 exposures

#### 4.1.2 Laboratory Values
- TSH, Free T4, Free T3, Thyroglobulin, TgAb
- CBC with differential, comprehensive metabolic panel
- Pregnancy test (β-hCG) for women of childbearing age
- Optional: 24-hour urinary iodine excretion

#### 4.1.3 Imaging Studies
- Diagnostic radioiodine scans (I-123 or low-dose I-131)
- Neck ultrasound, CT/MRI as available
- DICOM metadata extraction for uptake measurements

#### 4.1.4 Medications and Exposures
- Current medications with interaction checking
- Recent iodine-containing contrast exposure
- Supplements and over-the-counter medications

### 4.2 System Integrations
#### 4.2.1 Electronic Health Records
- HL7/FHIR compatibility for patient data exchange
- Real-time lab result integration
- Medication reconciliation with pharmacy systems

#### 4.2.2 Clinical Systems
- PACS integration for imaging report ingestion
- Nuclear medicine scheduling systems
- Radiation safety monitoring platforms

### 4.3 User Interface Requirements
#### 4.3.1 Clinician Dashboard
- **One-page overview**: Patient eligibility, preparation status, safety checklist
- **Workflow guidance**: Step-by-step protocol management
- **Alert system**: High-priority contraindications and drug interactions
- **Documentation tools**: Structured note generation, consent forms

#### 4.3.2 Patient Portal
- **Educational content**: Preparation instructions, diet guidelines
- **Interactive checklists**: Medication holds, symptom monitoring
- **Appointment reminders**: Preparation milestones, follow-up visits
- **Multilingual support**: English and Hindi for Indian market

## 5. Features and Functionality

### 5.1 Eligibility Assessment Module
#### 5.1.1 Automated Screening
- Rule-based contraindication checking with severity scoring
- Drug interaction analysis with timing recommendations
- Risk stratification based on patient characteristics
- Pregnancy verification workflows with documentation

#### 5.1.2 Clinical Decision Support
- Guideline-based dose recommendations (advisory only)
- TSH stimulation protocol selection assistance
- Timing optimization for multiple clinical factors
- Alternative therapy suggestions for ineligible patients

### 5.2 Preparation Management System
#### 5.2.1 Protocol Coordination
- Customizable preparation timelines (4-6 week planning horizon)
- Medication hold scheduling with reminder notifications
- Diet counseling with region-specific food alternatives
- Lab scheduling optimization for TSH monitoring

#### 5.2.2 Patient Engagement Tools
- Daily preparation checklists with progress tracking
- Educational videos and interactive content
- Symptom reporting with severity assessment
- Direct communication channels with care team

### 5.3 Safety and Monitoring Platform
#### 5.3.1 Radiation Safety Workflows
- Room preparation checklists with regulatory compliance
- Waste handling protocols with decay calculations
- Contamination monitoring documentation
- Staff exposure tracking and ALARA principles

#### 5.3.2 Post-therapy Surveillance
- Discharge criteria verification with radiation surveys
- Patient instruction delivery with comprehension testing
- Follow-up appointment scheduling with clinical priorities
- Adverse event reporting with CTCAE grading

### 5.4 Quality Assurance and Compliance
#### 5.4.1 Clinical Governance
- Version-controlled knowledge base with update tracking
- Medical advisory board review workflows
- Literature integration with evidence grading
- Override analysis and pattern recognition

#### 5.4.2 Regulatory Compliance
- AERB guideline adherence monitoring
- International standards alignment (IAEA, EANM)
- Privacy protection with encryption and access controls
- Audit trail maintenance for regulatory inspections

## 6. Non-Functional Requirements

### 6.1 Performance Standards
- **Response Time**: <2 seconds for eligibility checking
- **Availability**: 99.5% uptime during business hours
- **Scalability**: Support 100+ concurrent users
- **Data Processing**: Real-time lab result integration

### 6.2 Security and Privacy
- **Encryption**: AES-256 for data at rest and in transit
- **Authentication**: Multi-factor authentication for clinical users
- **Authorization**: Role-based access control with audit logging
- **Data Retention**: Configurable retention policies per local regulations

### 6.3 Usability Requirements
- **Learning Curve**: <2 hours training for clinical staff
- **Mobile Compatibility**: Responsive design for tablets and smartphones
- **Accessibility**: WCAG 2.1 AA compliance for visual/hearing impairments
- **Language Support**: English and Hindi with expandable framework

## 7. Success Metrics and KPIs

### 7.1 Clinical Outcomes
- **Safety Incidents**: Zero preventable contraindication oversights
- **Preparation Compliance**: >95% adherence to protocol timelines
- **Patient Satisfaction**: >4.5/5 rating for preparation experience
- **Clinical Efficiency**: 30% reduction in preparation-related delays

### 7.2 System Performance
- **User Adoption**: >80% active usage by target clinicians within 3 months
- **Data Accuracy**: >99% concordance with manual eligibility assessments
- **Alert Relevance**: <5% false-positive rate for high-priority alerts
- **Integration Success**: >95% successful EHR data synchronization

### 7.3 Quality Measures
- **Guideline Adherence**: >95% compliance with standard protocols
- **Documentation Completeness**: 100% structured data capture
- **Training Effectiveness**: <2% user error rate after initial training
- **Regulatory Compliance**: Zero violations in audit assessments

## 8. Risk Management and Mitigation

### 8.1 Clinical Risks
- **Missed Contraindications**: Comprehensive validation against multiple guidelines
- **Dosing Errors**: Clear advisory-only labeling with physician confirmation
- **Patient Safety**: Redundant checking systems and manual override capabilities
- **Regulatory Non-compliance**: Regular guideline updates and audit trails

### 8.2 Technical Risks
- **System Downtime**: Redundant infrastructure with failover capabilities
- **Data Loss**: Automated backups with point-in-time recovery
- **Integration Failures**: Graceful degradation with manual data entry options
- **Security Breaches**: Multi-layered security with incident response plans

### 8.3 Operational Risks
- **User Resistance**: Comprehensive training and change management support
- **Workflow Disruption**: Phased implementation with parallel legacy systems
- **Maintenance Burden**: Automated monitoring with predictive maintenance
- **Scalability Limitations**: Cloud-native architecture with elastic scaling

## 9. Implementation Timeline

### 9.1 Phase 1: Core Development (Weeks 1-8)
- **Weeks 1-2**: Requirements validation and system architecture
- **Weeks 3-4**: Rule engine development and eligibility module
- **Weeks 5-6**: Patient portal and preparation workflow tools
- **Weeks 7-8**: Safety module and basic integrations

### 9.2 Phase 2: Integration and Testing (Weeks 9-12)
- **Weeks 9-10**: EHR integration and data validation
- **Weeks 11-12**: User acceptance testing and clinical validation

### 9.3 Phase 3: Pilot Deployment (Weeks 13-16)
- **Weeks 13-14**: Limited pilot with 20-50 patients
- **Weeks 15-16**: Feedback integration and production readiness

## 10. Future Enhancements

### 10.1 Advanced Features (Phase 2)
- **Dosimetry Calculations**: MIRD-based absorbed dose estimation
- **Imaging Integration**: Automated uptake measurement from DICOM
- **Predictive Analytics**: Response prediction based on patient characteristics
- **Population Health**: Cohort analysis and outcome benchmarking

### 10.2 Expansion Opportunities (Phase 3)
- **Multi-isotope Support**: Lu-177 DOTATATE and Lu-177 PSMA protocols
- **International Deployment**: European and US regulatory compliance
- **Research Integration**: Clinical trial recruitment and data collection
- **AI Enhancement**: Machine learning for protocol optimization

## 11. Conclusion

This PRD establishes the foundation for developing a comprehensive AI assistant for I-131 therapy that prioritizes patient safety, clinical efficiency, and regulatory compliance. The system will serve as a model for nuclear medicine clinical decision support tools, with potential for expansion to other radionuclide therapies and international markets.

The success of this initiative will be measured by improved patient outcomes, enhanced clinical workflows, and demonstrated compliance with evolving regulatory requirements in the rapidly advancing field of precision nuclear medicine.
